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learn to recognize the markers and direct an immune 
response towards the tumour. However, early promise in 
this research led to disappointment during clinical trials. It 
appears that tumours have the ability to hijack and switch 
off the immune system and create an environment for 
themselves in which cancerous cells cannot be recognized 
as something to be destroyed.
Another approach involves the use of antibodies to 
perturb cell-to-cell communication by masking a protein 
marker on the tumour cell. This intervention can, for 
example, deprive the cell of some essential metabolic 
process or, via a different process, stimulate cell-to-cell 
communication and ‘turn on’ immune cells that destroy 
the cancer cells. The idea is that a ‘monoclonal’ antibody, 
raised against a specific antigen, will only work on that 
target and should, in theory, only destroy cancerous cells 
and not the healthy ones. 
A series of markers called checkpoint inhibitors (Figure 
1), work by blocking proteins that stop the immune system 
attacking cancer cells. Once these proteins are taken out of 
the process, the immune system can then get on with the 
job of destroying cancer cells. 
The problem researchers have found, however, is 
that cancerous cells have methods to adapt and evade 
treatments. By their very nature, cancer cells have 
accumulated mutations in their DNA and, in a process 
similar to evolutionary natural selection, those cells 
that have the necessary mutations required to survive a 
treatment will form the next generation of tumour cells 
resistant to that treatment and, all too often, the tumour 
comes back or relapses.
This brings us to the latest candidate for 
immunotherapy, chimeric antigen receptor T-cell therapy 
or CAR-T. This approach involves taking a T cell (so called 
because it matures in the thymus) from a patient and using 
There have been several attempts to investigate 
immunotherapy as a course of cancer treatment. In 
the late 1800s, clinicians noted their patients’ tumours 
sometimes shrank following a bacterial, viral or even 
fungal infection that had induced a feverish response. 
From this observation, Dr William Coley formulated a 
vaccine made of ‘killed’ bacteria and also noted that the 
tumours often contained large numbers of lymphocytes 
(white blood cells) that had infiltrated into the centre of 
the tumour. 
Over 100 years later we are still investigating the 
role these cells play in cancer and, as is usual in scientific 
advancement, it has become a lot more complex than 
previously imagined.
 
Different approaches to immunotherapy
Whilst there are numerous avenues of research into 
immunotherapeutic treatment, the basic concept 
of immunotherapy utilizes the specific molecular 
characteristics of tumour cells to bring about their 
destruction. In any form of therapy, there has to be a way 
to differentiate healthy cells and tissue from diseased, and 
immunotherapy is no different. This can be achieved by 
identifying specific unique markers of the tumour cells, 
usually proteins expressed either on the surface of a cell or 
within the cell itself. These molecules are sometimes part 
of the pathway by which cell-to-cell communication takes 
place, an important process in the development and spread 
of cancer.
Early on, immunotherapy researchers used a specific 
kind of immune cell called dendritic cells that play a role in 
cancer recognition. They mixed these cells, taken from the 
patient, with tumour cells so that the dendritic cell would 
Immunotherapy in cancer treatment
The human immune system provides a powerful response to invading organisms, destroying 
bacteria and viruses, as well as aberrant cells that turn cancerous and proliferate uncontrollably. 
The enquiring mind naturally wonders whether this system could be exploited to treat cancers 
that have somehow evaded our immune defences. Those cancers that do not respond to 
chemotherapy or radiotherapy, necessarily harsh and sometimes ineffective treatments, could 
potentially be thwarted by harnessing the power of our antibodies. Evidence to date suggests 
that this approach is feasible, although there is still much work to be done before we can say we 
have finally found a ‘cure’ via this route.
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a viral vector to insert a DNA sequence into the genome 
of this immune cell. In this way, it is possible to engineer a 
cell that expresses a receptor on its surface which identifies 
a tumour-specific surface protein and triggers destruction 
of the cancerous cell, without harming healthy cells. 
This system has proven successful in the treatment 
of some forms of blood cancer, which express a single, 
identifiable and cancer-specific target called CD19. 
However, problems start to appear when we try to translate 
that approach towards other cancers, such as solid tumours. 
In these diseases, the tumour is very often heterogeneous 
(Figure 2) which means that the markers we are looking 
for are present in some areas of the tumour but not in 
others. In addition, the markers can come and go during 
the course of the illness at different times making it almost 
impossible to pin down with a treatment like CAR-T.
Angiogenesis and immunosuppression
The crucial question that remains is whether CAR-T can 
be modified to reproduce the success seen with blood 
Figure 1. Checkpoint 
inhibitors, both inhibitory 
and stimulatory, of the 
immune system and 
their interactions with 
tumour cell markers. 
PD-1, programmed death-1; 
PD-L1, programmed 
death ligand-1; MHC, 
multi histocompatibility 
complex; CD, cluster of 
differentiation, CTLA-4, 
cytotoxic T lymphocyte 
associated protein-4; INF-γ, 
interferon gamma; TCR, 
T cell receptor (Ross and 
Jones (2017) Clin Sci. 131 
(21), 2627–2642).
Image used under the 
creative commons license.
cancer into the treatment of solid tumours, such as brain 
cancer. The answer may lie in targeting angiogenesis and 
immunosuppression, two ‘hallmarks of cancer’, which are 
characteristic of malignant tumours.
Angiogenesis simply means the creation of new blood 
vessels. One of the defining properties of a malignant cancer 
is the ability for it to spread to other parts of the affected 
organ, as well as to other sites in the body. To do this the 
tumour creates its own network of blood vessels to sustain 
itself on its travels. The process of angiogenesis is driven by 
a specific cell-to-cell signalling mechanism, which involves 
the collision and interaction of specific molecules on the 
surface of tumour cells, as well as the newly created blood 
vessels. These molecules could be a potential new target for 
CAR-T therapy.
Immunosuppression means the dampening down 
of the immune system, and is a necessary process that is 
meant to stop our immune system attacking our own cells, 
as well as those of any offspring we may be carrying. To this 
end it is a vital function to enable life to continue. However, 
cancers have a sneaky way of subverting this process to 
avoid monitoring by the immune system. During the 
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progression of a cancerous disease, a modification often 
occurs to generate a tumour-promoting role for the 
immune system. This dual role of tumour promotion 
and tumour protection is termed immunoediting and 
has three phases: elimination, which is the recognition 
of cancer cells by the immune system, equilibrium, in 
which the expansion of cancer cells is controlled by the 
immune system and escape, which is the development of 
an immunosuppressive tumour microenvironment.
One of the principal architects of this 
immunosuppressive microenvironment is a specific 
regulatory T-cell, or Treg for short. Look inside most solid 
tumours and you will see that these cells have infiltrated 
into the middle of the tumour, attracted by cell-signalling 
proteins called cytokines, which are produced by the 
tumour itself to create its own ‘safe space’ within the body. 
The brain has long been thought of as an immunologically 
privileged site, with the tight junctions of blood vessel 
endothelial cells providing a blood–brain barrier that 
prevented the infiltration of T lymphocytes into the central 
nervous system. However, under the pathological state 
of a tumour, the blood–brain barrier is disrupted and 
lymphocyte trafficking to the brain increases. Immune-
competent lymphocytes that can get to the site, however, 
are immediately switched off by those unwelcome Treg 
cells that have been brought in by the tumour to do this 
very job. The question emerges then, can these Tregs also 
be destroyed by engineered CAR-T cells designed to take 
them out of the tumour site?
Toxicity and limitations of CAR-T
One of the main limitations of CAR-T therapy is toxicity 
associated with the treatment. Although you have a specific 
target in mind for your engineered cells, there can be cross-
reactivity with other molecules on healthy cells. In addition, 
the immune system can be overstimulated, leading to a 
condition known as cytokine release syndrome (CRS). CRS 
is caused by a sudden and overpowering release of cytokines 
from the lymphocytes, stimulated by the CAR-T cells, and 
this can cause an onset of nausea, rashes and difficulty 
breathing. On some occasions this can be life-threatening. 
To avoid this, the CAR-T target must be as specific as 
possible to the tumour cell. It would appear that targeting 
cells involved in angiogenesis and immunosuppression 
would lead to exactly this sort of non-specific reactivity, 
since both of these are normal processes involved in the 
healthy functioning of our bodies. 
Overcoming the limitations
 
But what if a specific marker could be found for solid 
tumour angiogenesis or for Tregs that infiltrate into 
tumours? The possibility of targeting those tumours 
would then become feasible. These markers are 
unlikely to change, because the process of angiogenesis 
is not normally targeted by the immune system in the 
same way as cancer cells, and so there has been less 
time for resistance to the immune system to develop. 
Another way of overcoming tumour heterogeneity 
is by producing CAR-T cells with multiple antigen-
binding regions. The fourth generation of CAR-T 
allows cells to have the ability to bind more than one 
target, making it possible for the CAR-T producer to 
refine their target to make sure healthy cells are not 
attacked (Figure 3). CAR-T cells unresponsive to the 
immunosuppressive properties of the solid tumour 
could also be produced, as well as those that have an 
amplified response to the target. This could be done 
by engineering a pro-inflammatory response to the 
CAR-T when it is bound to the specific target you are 
looking for.
The potential for CAR-T therapy to treat solid 
tumours as well as blood cancers is very exciting. The 
search for a good, reliable target that causes negligible 
side-effects, is resistant to tumour heterogeneity and 
the immunosuppressive micro-environment will be 
key to expanding the horizons of this therapy. Finding 
these markers is the current focus of my research. To 
this end I am investigating a range of angiogenesis 
markers called platelet-derived growth factors 
(PDGF). This molecule and its receptor is strongly 
implicated in the angiogenesis process and, from my 
Figure 2. Immunohistochemistry of glioma tissue. The marker labelled (CD25) in red is not 
present in all parts of the tumour showing its heterogeneous nature. Image produced by 
the author.
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experiments, is found in increased amounts in the sera 
of brain cancer patients compared with the sera from 
healthy control participants. This finding suggests that 
this may be an appropriate place to start looking for a 
unique and significant isoform of PDGF from which 
an effective CAR-T therapy may be formulated.■
Figure 3. Classes of CAR-T cells showing increased functionality of the cell by the addition of co-stimulatory domains and the addition of genes to produce 
cytokines or a co-stimulatory ligand. TRUCK, T cells redirected for antigen-unrestricted cytokine-initiated killing; ITAM, immunoreceptor tyrosine-based 
activation motif (Sha, H-H., Wang, D-D., Yan, D-I., Hu, Y., Yang, S-J., Liu, S-W. and Feng, J-F. (2017) Bioscience Reports, 37 (1), BSR20160332).
Image used under the creative commons license. 
Further reading
• Říhová, B. and Šťastný, M. (2015) History of immuno-
therapy – from Coley toxins to check-points of the 
immune reaction. Klin Onkol. 28(4),4S8–14
• Annesley, C., Summers, C., Ceppi, F. and Gardner, R.A. 
(2018) The evolution and future of CAR T cells for 
B-cell acute lymphoblastic leukemia. Clin Pharmacol & 
Therapeutics, 103(4), 591–598
• Mao, G., Sampath, P. and Sengupta, S. (2017) Updates 
on chimeric antigen receptor-mediated glioblastoma 
immunotherapy, R I Med Jour. 100(6), 39–42
• Chinnasamy, D., Yu, Z., Theoret, M.R., Zhao, Y., Shrimali, 
R.K., Morgan, R.A., Feldman, S.A., Restifo, N.P. and 
Rosenberg, S.A. (2010) Gene therapy using genetically 
modified lymphocytes targeting VEGFR-2 inhibits the 
growth of vascularized syngenic tumors in mice. J Clin 
Invest. 120(11), 3953–3968
• Sha, H-H., Wang, D-D., Yan, D-I., Hu, Y., Yang, S-J., 
Liu, S-W. and Feng, J-F. (2017) Chimaeric antigen 
receptor T-cell therapy for tumor immunotherapy.
Bioscience Reports, 37(1) BSR20160332 doi: 10.1042/
BSR20160332
• Ross, K. and Jones, R.J. (2017) Immune checkpoint 
inhibitors in renal cell carcinoma. Clin Sci. 131(21), 
2627–2642
Dr Peter Abel spent 19 years working for 
the NHS in haematology departments 
before taking a senior lecturing post at 
the University of Central Lancashire in 
the School of Pharmacy and Biomedical 
Sciences. He is Course Leader for the 
undergraduate Healthcare Science 
degree and supervises placement provision within the NHS 
pathology laboratories allied to his course. In research he is a 
member of the Brain Tumour North West research alliance and 
is interested in immunosuppression and the search for a blood-
borne biomarker for glioblastoma. He is currently looking for a 
novel target for potential use in adoptive cell transfer therapy. 
Email: pabel@uclan.ac.uk
D
ow
nloaded from
 https://portlandpress.com
/biochem
ist/article-pdf/41/1/8/851489/bio041010008.pdf by U
niversity of C
entral Lancashire user on 23 O
ctober 2019
